The molecular mechanism by which ADI inhibits NSCLC metastasis involves the regulation of the PLAT/FAK/AKT pathway to suppress the migration and invasion of gefitinib-resistant PC9GR cells. Here, PTK2 is linked to non-small cell lung carcinoma.